GSEP
TVTX icon

Golden State Equity Partners’s Travere Therapeutics TVTX Stock Holding History

Golden State Equity Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-98
Closed -$2.91K – 1641
2026
Q1 		$2.91K Buy
+98
New +$2.93K ﹤0.01% 1586

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Golden State Equity Partners's TVTX Position: Q2 2026 in Review

Golden State Equity Partners sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 98 shares — an estimated $2.91K sold.

Golden State Equity Partners first reported a position in TVTX in Q1 2026 and held it in 1 quarter. The position peaked at $2.91K in Q1 2026. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Golden State Equity Partners reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 98 Travere Therapeutics shares in Q2 2026, an estimated $2.91K.
  • Golden State Equity Partners first reported a position in Travere Therapeutics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Travere Therapeutics position peaked at $2.91K in Q1 2026.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.